Can GW Pharmaceuticals Continue Higher?

NASDAQ: GWPH | GW Pharmaceuticals Plc News, Ratings, and Charts

GWPH – After a downgrade, can GW Pharmaceuticals (GWPH) go higher.

 

Yesterday, GW Pharmaceuticals (GWPH) fell 3% after Stifel analyst Paul Matteis downgraded the company due to disappointing physician feedback regarding “off-label” use of the drug Epidiolex. Matteis cut his rating to hold after maintaining a buy rating for at least two years. He also cut his target price to $140 from $150. 

Matteis noted that the downgrade wasn’t a call on GW’s second-quarter results expected in early August. He stated that he believes the company will beat expectations as the impact of COVID-19 doesn’t seem as bad as projected. Matteis said, “Instead, what’s led to a change in our view is conservative physician expectations for Epidiolex use in ‘off-label’ refractory epilepsy, whereas we believe substantial uptake here is: 1) key to the bull case; and 2) necessary to meet or beat 2021-2025 consensus sales projections.” 

GWPH is up over 40% for the past three months, while the Spinnaker Cannabis ETF (THCX) has climbed 22.5%. The stock has been outperforming the cannabis sector, but the question remains whether that will continue. Here are a few reasons why I believe that’s possible. 

First, I expect Epidiolex sales revenue to remain strong in North America and Europe. This should enable the company to fuel future growth initiatives and research moving forward. Profitability in the cannabis sector has been the biggest concern for investors over the past two years. As GWPH gets closer to profitability, it should provide support for the stock. GWPH should also benefit from new revenue streams as Epidiolex will be prescribed for the treatment of TSC in the 2nd half of the year.

GWPH also recently announced that it is researching the use of Nabiximols in treating a range of spasticity conditions. Nabiximols, brand name Sativex, is a specific cannabis extract approved in 2010 as a botanical drug in the United Kingdom. Nabiximol is a combination of THC and CBD. It is sold as a mouth spray intended to alleviate neuropathic pain, spasticity, overactive bladder, and other symptoms related to multiple sclerosis. Phase 3 trials for the drug should start in the second half of 2020. 

Despite Paul Matteis’s downgrade, many analysts remain bullish on the stock. On June 30th Evercore ISI analyst Joshua Schimmer raised his rating to Outperform on GWPH and established a new price target of $275 based on the potential of Nabiximols.

Want More Great Investing Ideas?

9 “BUY THE DIP” Growth Stocks for 2020

Newly REVISED 2020 Stock Market Outlook

7 “Safe-Haven” Dividend Stocks for Turbulent Times


GWPH shares were trading at $135.95 per share on Thursday afternoon, up $0.40 (+0.30%). Year-to-date, GWPH has gained 30.02%, versus a 0.53% rise in the benchmark S&P 500 index during the same period.


About the Author: Aaron Missere


Aaron is an experienced investor who is also the CEO of Departures Capital. His primary focus is on the cannabis industry. He also hosts a weekly show on YouTube about marijuana stocks. Learn more about Aaron’s background, along with links to his most recent articles. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
GWPHGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Does Trump Change Stock Market Outlook?

The rally of the S&P 500 (SPY) after the election gives a sense that investors are happy that Trump was elected. But perhaps there is more to this story than meets the eye. That’s why Steve Reitmeister shares his updated market outlook taking into account the pros and cons of Trumps proposed new policies. This comes with a preview of his top 11 stocks to buy now.

3 Streaming Stocks Benefiting from Cord-Cutting Trends

As streaming continues to dominate the digital entertainment landscape, the global streaming market presents a lucrative investment opportunity. So, it could be ideal to invest in fundamentally solid streaming stocks Netflix (NFLX), Walt Disney (DIS), and Roku (ROKU). Read further...

3 Gold Stocks to Buy as Safe-Haven Demand Grows

Gold is a stable investment now due to its role as a safe-haven asset during economic uncertainty, rising demand, industrial use, and growth, bolstered by central bank purchases and interest rate cuts. Therefore, investors should consider investing in top gold stocks such as Newmont (NEM), Barrick Gold (GOLD), and Agnico Eagle Mines (AEM). Read more...

3 AI Stocks Transforming Industries and Driving Future Growth

With rapid digitalization, rapid adoption, and development, as well as surging demand, the AI market is on the rise. Amid this backdrop, investors could buy fundamentally solid AI stocks NVIDIA Corporation (NVDA), Microsoft (MSFT), and Meta Platforms (META) poised for substantial gains. Continue reading...

Updated Stock Market Expectations

The S&P 500 (SPY) has already reached an impressive goal of hitting 6,000. Yet you can see how much shares are struggling now up against this resistance. Steve Reitmeister shares his views on what comes next for the market and his top 10 stocks to stay on the right side of the action.

Read More Stories

More GW Pharmaceuticals Plc (GWPH) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All GWPH News